Arrowhead Pharmaceuticals — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ARO-MAPT-SCStudy to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.	Alzheimer	Phase 1/2	À vérifier	Canada, New Zealand	À vérifier
ARO-MAPT-SCStudy to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.	Alzheimer	Phase 1/2	À vérifier	Canada, New Zealand	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
ARO-MAPT-SC	Alzheimer	Phase 1/2	NCT07221344	Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.